Mike Bellin, U.S. IPO services leader at PricewaterhouseCoopers, says the IPO market remains selective but open to companies with strong fundamentals. Year to date, the U.S. has seen just under 90 traditional IPOs, below the 125 to 175 that marks a good year. The market showed broad strength through the first three quarters across industrial products, tech, consumer, energy, utilities and financial services, but momentum halted significantly in September and October.
Bellin attributes the slowdown to macro uncertainty around rates, inflation and geopolitical concerns, as well as aggressive valuations in some offerings. He said many issuers decided to pause and wait for another window.
Public market investors now focus on durable revenue backed by strong and diverse customers, significant backlogs of demand, and reasonable leverage ratios. Bellin noted that scale matters. Larger companies can dictate their IPO timing, while smaller and midmarket companies outside biotech face tighter constraints.
On AI companies, Bellin said investors are not skeptical of AI itself but of spending without visibility to future earnings. The market separates AI companies with visible demand and growth from those with only a narrative. Profitability, cash generation and free cash flows matter more than ever.
Biotech has seen strong momentum, driven by M&A activity. As large pharmaceutical companies lose patents on profitable drugs, they compete for next-generation biotech assets, creating a choice between IPO upside and M&A certainty for founders.
SPACs are attracting renewed interest because they set valuation certainty on day one, and serial SPAC issuers understand which de-SPAC candidates can deliver growth and hit milestones.
Bellin said hundreds of companies are in the pipeline ready to go when market conditions allow. He expects momentum from private equity, energy, consumer and industrial products to build through late 2026 and into early 2027.